
Glaukos (GKOS) Stock Forecast & Price Target
Glaukos (GKOS) Analyst Ratings
Bulls say
Glaukos is a strong investment opportunity based on their impressive pipeline and potential for long-term growth. With consistently strong revenue growth and a robust portfolio of products, Glaukos is well-positioned to maintain core market share and see strong contributions from new products such as iDose and Epioxa. Additionally, their innovative approach to ophthalmic treatments and partnerships with major players in the medical industry further solidify their potential for future success.
Bears say
Glaukos is experiencing strong revenue growth and is making investments in their pipeline. However, there are four key risks that may impact their success: sales execution, competition in the MIGS market, reimbursement obstacles, and slow market adoption of their Corneal Health products. Despite positive gross and operating margins, there is still potential for challenges in market access and continued competition in the ophthalmic medical technology and pharmaceutical industry.
This aggregate rating is based on analysts' research of Glaukos and is not a guaranteed prediction by Public.com or investment advice.
Glaukos (GKOS) Analyst Forecast & Price Prediction
Start investing in Glaukos (GKOS)
Order type
Buy in
Order amount
Est. shares
0 shares